### Clinical Pharmacology

Disease Progress + Drug Action

#### **Models**

### • Pharmacokinetic (dose, concentration, time)

- drug disposition in individuals & populations
- disease state effects (renal & hepatic dysfunction)
- intervention effects (hemodialysis)
- concurrent medication effects
- pharmacogenetic influences

## • Pharmacodynamic (dose or concentration, effect)

- physiologic & biomarkers
- surrogate endpoints
- clinical effects and endpoints

### **Disease Progression Model**

- Quantitative model that accounts for the time course of disease, S(t), untreated and treated as assessed by
  - "Symptoms" measures of how a patient feels or functions ("clinical endpoints")
  - "Signs" physiological or biological measurements of disease activity ("biomarkers")
    - May be linked to "Surrogate Endpoints" (biomarkers that achieve surrogacy status) or "Outcomes" (omnibus measures of global disease states such as pre-defined progression or death)

### Motivations for Disease Progression Models

- Visualization of the time course of disease in treated and untreated conditions
- Evaluation of various disease interventions
- Simulation of possible future courses of disease
- Simulation of clinical trials

### **Model Building Process**

- Talk to a Disease Specialist
- Draw pictures of time course of disease
- Translate into disease progress model
- Explain the models/parameters
- Ask Disease Specialist for advice on factors influencing parameters
- Translate into models of parameters adapted from Holford 1999

## Components of a Disease Progression Model


- Baseline Disease State,  $S_o$
- Natural History
- Placebo Response
- Active Treatment Response

$$S(t) = Nat. Hx. + Plac + Active$$

### Linear (Natural History) Disease Progression Model


(adapted from Holford 1999)

$$S(t) = S_0 + \mathbf{a} \cdot t$$




### Linear Disease Progression Model with Temporary ("Offset") Placebo or Active Drug Effect

(adapted from Holford 1997 & 1999)




# Prednisone Treatment of Muscular Dystrophy




Griggs et al. Arch Neurol (1991); 48: 383-388

### **AZT Treatment of HIV**



Sale et al, Clin Pharm Ther (1993) 54:556-566

# Tacrine Treatment of Alzheimers Disease




Holford & Peace, Proc Natl Acad Sci 89 (1992):11466-11470

# Tacrine Treatment of Alzheimers Disease


- Baseline Disease State:  $S_o$
- Natural History:  $S_0 + a \cdot t$
- Placebo Response:  $b_p \cdot Ce_p(t)$
- Active Treatment Response:  $b_a \cdot Ce_a(t)$

# Tacrine Treatment of Alzheimers Disease




Holford & Peace, Proc Natl Acad Sci 89 (1992):11466-11470

## Linear Disease Progression Model with Disease Modifying ("Slope") Active Drug Effect



### Alternative Drug Effect Mechanisms Superimposed on a Linear Natural History Disease Progression Model

adapted from Holford 1999



### Asymptotic Progress Model


- Zero Asymptote (R<sub>0</sub>, Tprog)
  - Spontaneous recovery

$$S(t) = R_0 \bullet e^{-\ln(2)/Tprog \bullet t}$$


- Non-Zero Asymptote (Rss, Tprog)
  - Progression to "burnt out" state

$$S(t) = Rss \cdot \left(1 - e^{-\ln(2)/Tprog \cdot t}\right)$$

### Asymptotic Progress Model




## Physiological Disease Progress




to produce disease progression

#### 4 Basic Mechanisms



### Inhibition of Loss



### Disease Progress Models

- Alzheimer's Disease
  - Linear: Drug effect symptomatic
- Diabetic Neuropathy
  - Linear: Drug effect both?
- Osteoporosis
  - Inhibition of Bone Loss (oestrogen)
- Parkinson's Disease
  - Asymptotic: Drug effect both?